Protagonist Therapeutics segnala gli utili su base trimestrale. Questi report sugli utili trimestrali offrono agli investitori uno sguardo ai risultati finanziari di un'azienda per un periodo di 3 mesi. I report sugli utili includono quasi sempre i risultati EPS e i ricavi.
Analizza lo storico degli utili di Protagonist Therapeutics utilizzando ordinamenti e filtri avanzati.
Get Alert | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
PTGX | Protagonist Therapeutics | -$0.54 | -$0.62 | -$0.62 | 0.00% | $4.67M | $6.48M | $4.71M | -27.30% | 11/06/2025 | |
PTGX | Protagonist Therapeutics | -$0.50 | -$0.53 | -$0.55 | -3.77% | $4.17M | $9.15M | $5.55M | -39.39% | 08/06/2025 | |
PTGX | Protagonist Therapeutics | $3.26 | $0.11 | -$0.19 | -272.73% | $254.95M | $30.44M | $28.32M | -6.96% | 05/06/2025 | |
PTGX | Protagonist Therapeutics | $0.44 | $1.03 | $1.98 | 92.23% | $60.00M | $53.52M | $170.64M | 218.83% | 02/21/2025 | |
PTGX | Protagonist Therapeutics | -$0.58 | -$0.63 | -$0.54 | 14.29% | $0.00 | $2.07M | $4.67M | 125.74% | 11/07/2024 | |
PTGX | Protagonist Therapeutics | -$0.68 | -$0.60 | -$0.50 | 16.67% | $0.00 | $8.00M | $4.17M | -47.91% | 08/06/2024 | |
PTGX | Protagonist Therapeutics | -$0.67 | $2.51 | $3.26 | 29.88% | $0.00 | $120.00M | $254.95M | 112.46% | 05/07/2024 | |
PTGX | Protagonist Therapeutics | -$0.69 | -$0.03 | $0.44 | 1566.67% | $0.00 | $40.00M | $60.00M | 50.00% | 02/27/2024 | |
PTGX | Protagonist Therapeutics | -$0.64 | -$0.70 | -$0.58 | 17.14% | $0.00 | $10.00M | $0.00 | -100.00% | 11/02/2023 | |
PTGX | Protagonist Therapeutics | -$0.84 | -$0.65 | -$0.68 | -4.62% | $859.00K | — | $0.00 | — | 08/03/2023 | |
PTGX | Protagonist Therapeutics | -$0.43 | -$0.73 | -$0.67 | 8.22% | $25.72M | $2.00M | $0.00 | -100.00% | 05/04/2023 | |
PTGX | Protagonist Therapeutics | -$0.77 | -$0.59 | -$0.69 | -16.95% | $8.62M | $5.00M | $0.00 | -100.00% | 03/15/2023 | |
PTGX | Protagonist Therapeutics | -$0.70 | -$0.87 | -$0.64 | 26.44% | $10.29M | — | $0.00 | — | 11/08/2022 | |
PTGX | Protagonist Therapeutics | -$0.69 | -$0.93 | -$0.84 | 9.68% | $2.27M | $380.00K | $859.00K | 126.05% | 08/04/2022 | |
PTGX | Protagonist Therapeutics | -$0.54 | -$0.63 | -$0.43 | 31.75% | $6.19M | $17.05M | $25.72M | 50.86% | 05/04/2022 | |
PTGX | Protagonist Therapeutics | -$0.48 | -$0.78 | -$0.77 | 1.28% | $5.65M | $5.07M | $8.62M | 69.96% | 02/28/2022 | |
PTGX | Protagonist Therapeutics | -$0.21 | -$0.67 | -$0.70 | -4.48% | $13.11M | $1.74M | $10.29M | 491.15% | 11/03/2021 | |
PTGX | Protagonist Therapeutics | -$0.59 | -$0.51 | -$0.69 | -35.29% | $6.22M | $7.31M | $2.27M | -69.02% | 08/04/2021 | |
PTGX | Protagonist Therapeutics | -$0.72 | -$0.57 | -$0.54 | 5.26% | $3.65M | $1.87M | $6.19M | 230.96% | 05/04/2021 | |
PTGX | Protagonist Therapeutics | -$0.63 | -$0.48 | -$0.48 | 0.00% | $2.72M | $3.12M | $5.65M | 81.09% | 03/10/2021 |
| Trimestre fiscale | Data segnalata | EPS effettivo | EPS stimato | Sorpresa% |
|---|---|---|---|---|
| Q3 | 2025-11-06 | $-0.62 | $-0.62 | 0.00 % |
| Q2 | 2025-08-06 | $-0.55 | $-0.53 | -3.77 % |
| Q1 | 2025-05-06 | $-0.19 | $0.11 | -272.7 % |
| Q4 | 2025-02-21 | $1.98 | $1.03 | 92.2 % |
| Trimestre fiscale | Data segnalata | Entrate effettive | Entrate stimate | Sorpresa% |
|---|---|---|---|---|
| Q3 | 2025-11-06 | $4.71M | $6.48M | -27.3 % |
| Q2 | 2025-08-06 | $5.55M | $9.15M | -39.4 % |
| Q1 | 2025-05-06 | $28.32M | $30.44M | -6.96 % |
| Q4 | 2025-02-21 | $170.64M | $53.52M | 218.8 % |
Protagonist Therapeutics (PTGX) non ha ancora previsto report sulle performance. L'ultimo report sui risultati è stato pubblicato il novembre 6, 2025 per il Q3.
Protagonist Therapeutics (PTGX) non ha ancora in programma alcun report sugli utili. L'ultimo report sugli utili è stato pubblicato il novembre 6, 2025 per il Q3 e l'EPS effettivo è stato $-0.62, che centrato la stima di $-0.62.
Protagonist Therapeutics (PTGX) non ha ancora pianificato alcun report sugli utili. L'ultimo report sugli utili è stato pubblicato il novembre 6, 2025 per il Q3 e i ricavi effettivi sono stati $4.7M, che mancato la stima di $6.5M.
Sfoglia stime sugli utili, EPS e ricavi su tutte le azioni.